SCHEMBL7417217

SCHEMBL7417217

CN(CCO)Cc1cccs1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 2/20 0.47
RIPK1 Q13546 1/20 0.46
ALDH1A1 P00352 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HPGD P15428 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
GAA P10253 2/20 0.45
POLB P06746 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
HSD11B1 P28845 2/20 0.43
CYP1A2 P05177 1/20 0.43
CHRM2 P08172 1/20 0.43
CHRM5 P08912 1/20 0.43
ADRA2A P08913 1/20 0.43
CYP2D6 P10635 1/20 0.43
CHRM1 P11229 1/20 0.43
CYP2C9 P11712 1/20 0.43
ADRA2B P18089 1/20 0.43
NFKB1 P19838 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL657171 0.84 SMN1; SMN2 (0.55) TRPM8RIPK1ALDH1A1SMN1; SMN2HPGD
SCHEMBL13696513 0.80 TAAR1 (0.46) TRPM8RIPK1ALDH1A1SMN1; SMN2HPGD
SCHEMBL11466844 0.79 MEN1 (0.51) TRPM8RIPK1ALDH1A1SMN1; SMN2HPGD
SCHEMBL14376819 0.77 MAPT (0.51) RIPK1ALDH1A1SMN1; SMN2HPGDMEN1
SCHEMBL27305404 0.77 SMN1; SMN2 (0.49) RIPK1ALDH1A1SMN1; SMN2HPGDMEN1
SCHEMBL1304013 0.76
SCHEMBL29955953 0.74 SMN1; SMN2 (0.50) RIPK1ALDH1A1SMN1; SMN2HPGDMEN1
SCHEMBL15720861 0.74 MAPT (0.48) ALDH1A1SMN1; SMN2HPGDMEN1KMT2A
Hydrochloric Acid SCHEMBL28582399 0.74 HPGD (0.53) TRPM8RIPK1ALDH1A1SMN1; SMN2HPGD
Ethane SCHEMBL8092722 0.74 TAAR1 (0.56) TRPM8RIPK1ALDH1A1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11718643-B2 Multimodal anion exchange matrices CYTIVA BIOPROCESS R&D AB (SE) 2023-08-08 US disclosed
US-11718643-B2 Multimodal anion exchange matrices CYTIVA BIOPROCESS R&D AB (SE) 2023-08-08 US disclosed
US-10815269-B2 Multimodal anion exchange matrices GE HEALTHCARE BIOPROCESS R&D AB (SE) 2020-10-27 US disclosed
US-20190023735-A1 Multimodal Anion Exchange Matrices GE HEALTHCARE BIOPROCESS R&D AB (SE) 2019-01-24 US disclosed
US-20150299248-A1 Multimodal Anion Exchange Matrices GE Healtchare Bio-Sciences AB (SE) 2015-10-22 US disclosed
US-20150299248-A1 Multimodal Anion Exchange Matrices GE Healtchare Bio-Sciences AB (SE) 2015-10-22 US disclosed
CN-1247593-C Thiepino [3, 2-b ] dihydropyridines and related compositions and methods ORTHO MCNEIL PHARM INC (US) 2006-03-29 CN disclosed
CN-1522257-A Thiepino[3,2-b]dihydropyridines and related compositions and methods ����-������ҩƷ��˾ 2004-08-18 CN disclosed
EP-1265903-A1 THIEPINO[3,2-B]DIHYDROPYRIDINES AND RELATED COMPOSITIONS AND METHODS Ortho-Mcneil Pharmaceutical, Inc. (US) 2002-12-18 EP disclosed
US-6420383-B1 CALCIUM CHANNEL BLOCKERS, HYPERSENSITIVITY, ALLERGY, ASTHMA, BRONCHOSPASM, DYSMENORRHEA, ESOPHAGEAL SPASM, GLAUCOMA, PREMATURE LABOR, URINARY TRACT DISORDERS, GASTROINTESTINAL MOTILITY DISORDERS AND CARDIOVASCULAR DISORDERS. ORTHO-MCNEIL PHARMACEUTICAL, INC. 2002-07-16 US disclosed
WO-2001070748-A1 THIEPINO [3,2-b] DIHYDROPYRIDINES AND RELATED COMPOSITIONS AND METHODS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2001-09-27 WO disclosed
CN-1038587-C 1,4-Dihydropyridines, process for preparation thereof and their application as medicinal products DELAGRANGE LAB (ES) 1998-06-03 CN disclosed
EP-0302980-B1 1,4-DIHYDROPYRIDINES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS LABORATORIOS DELAGRANGE S.A. (ES) 1991-03-13 EP disclosed
US-4952592-A HYPOTENSIVE, CARDIOTONIC AGENTS INSTITUTO DE INVESTIGACION Y DESARROLLO QUIMICOBIOLOGICO S.A. (ES) 1990-08-28 US disclosed
CN-1031531-A 1,4-dihydropyridine its preparation method and be used for the purposes of medicine DELAGRANGE LAB (ES) 1989-03-08 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10815269-B2 Multimodal anion exchange matrices H1-3, H1-4, IGF2R TRPM8 1460/4885RIPK1 3550/4885ALDH1A1 2226/4885
US-11718643-B2 Multimodal anion exchange matrices H1-3, H1-4, IGF2R TRPM8 1460/4885RIPK1 3550/4885ALDH1A1 2226/4885
US-20150299248-A1 Multimodal Anion Exchange Matrices H1-3, H1-4, IGF2R TRPM8 1460/4885RIPK1 3550/4885ALDH1A1 2226/4885
US-20190023735-A1 Multimodal Anion Exchange Matrices H1-3, H1-4, IGF2R TRPM8 1460/4885RIPK1 3550/4885ALDH1A1 2226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.